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ABSTRACT
Objectives The COVID- 19 pandemic has resulted in 
widespread morbidity and mortality with the consequences 
expected to be felt for many years. Significant variation exists 
in the care even of similar patients with COVID- 19, including 
treatment practices within and between institutions. Outcome 
measures vary among clinical trials on the same therapies. 
Understanding which therapies are of most value is not 
possible unless consensus can be reached on which outcomes 
are most important to measure. Furthermore, consensus 
on the most important outcomes may enable patients to 
monitor and track their care, and may help providers to 
improve the care they offer through quality improvement. To 
develop a standardised minimum set of outcomes for clinical 
care, the International Consortium for Health Outcomes 
Measurement (ICHOM) assembled a working group (WG) of 28 
volunteers, including health professionals, patients and patient 
representatives.
Design A list of outcomes important to patients and 
professionals was generated from a systematic review of the 
published literature using the MEDLINE database, from review 
of outcomes being measured in ongoing clinical trials, from a 
survey distributed to patients and patient networks, and from 
previously published ICHOM standard sets in other disease 
areas. Using an online- modified Delphi process, the WG 
selected outcomes of greatest importance.
Results The outcomes considered by the WG to be most 
important were selected and categorised into five domains: (1) 
functional status and quality of life, (2) mental functioning, (3) 
Strengths and limitations of this study
 ► These consensus recommendations were generat-
ed by a large international working group consisting 
of all relevant stakeholders with an interest in out-
comes of care for patients with COVID- 19.
 ► The diversity of the working group means that the rec-
ommendations included in the standard set are applica-
ble to all settings.
 ► The methodology employed in the generation of the 
standard set meant that the focus was on outcomes of 
relevance to patients throughout and there is a deliber-
ate emphasis on the use of patient- reported outcome 
measures in the set.
 ► SARS- CoV- 2 was discovered just over 1 year ago and so 
we cannot yet be certain about the long- term outcomes 
of the disease.
 ► ICHOM (International Consortium for Health Outcomes 
Measurement) standard sets typically undergo an open 
review process prior to publication, in which the draft set 
is distributed to patients and their representative groups 
for feedback; however, this was not possible for this 
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social functioning, (4) clinical outcomes and (5) symptoms. The WG identified 
demographic and clinical variables for use as case- mix risk adjusters. These 
included baseline demographics, clinical factors and treatment- related factors.
Conclusion Implementation of these consensus recommendations could help 
institutions to monitor, compare and improve the quality and delivery of care 
to patients with COVID- 19. Their consistent definition and collection could also 
broaden the implementation of more patient- centric clinical outcomes research.
INTRODUCTION
SARS- CoV- 2, the virus responsible for the COVID- 19 
pandemic, has infected almost 250 million people and 
resulted in the deaths of over 5 million.1 Although knowl-
edge about the acute illness has rapidly expanded, there 
is increasing evidence that COVID- 19 may have long- term 
sequelae, with adverse health outcomes and poor health- 
related quality of life lasting far longer than the acute 
disease.2
Significant variation exists in the care even of similar 
patients with COVID- 19, including treatment practices 
within and between institutions and countries.3 Further-
more, outcome measures vary among the largest clinical 
trials on the same therapies.4 Understanding which ther-
apies are of most value will remain a challenge unless 
consensus can be reached on which outcomes are most 
important to patients to measure. While survival or indi-
rect measures of patient’s health status, for example, 
hospitalisation, the need for mechanical or non- invasive 
ventilation, as well as measures of resource utilisation, are 
frequently recorded in trials, direct measures of patient- 
reported outcomes (PROs) are rarely measured and/or 
recorded.5 Furthermore, the follow- up period of many 
trials is insufficient to detect some outcomes affecting 
patients long after hospital discharge. There is, there-
fore, a need for a standardised approach to outcome 
measurement in COVID- 19 to inform clinical practice 
and real- world therapeutic research and to allow health-
care providers to monitor outcomes and to identify areas 
for quality improvement. A standard set of outcomes, that 
is, standardised outcomes, measurement tools and time 
points and risk adjustment factors for COVID- 19,6 could 
help benchmark best practice across institutions, facili-
tating improvements in care during future outbreaks and 
providing value in healthcare. It could also standardise 
approaches to global research for patient benefit.
To support the development of a standardised outcome 
set in COVID- 19 for integration into clinical practice (and 
to inform clinical research), the International Consortium 
for Health Outcomes Measurement (ICHOM) convened 
an international multidisciplinary Working Group (WG) 
of experts and patient representatives. As a not- for- profit 
organisation, ICHOM has developed 38 standard sets of 
value- based outcomes for use in routine clinical practice 
in a range of medical conditions, such as coronary artery 
disease, stroke and cancer.7 Over 600 organisations have 
implemented ICHOM sets including 15 national regis-
tries. Standard sets are reviewed and updated annually by 
ICHOM.
The aim of this paper is to present a standardised 
minimum set of outcomes for COVID- 19, focusing on the 
inclusion of PROs, and case- mix variables, for compari-
sons across treatment modalities and institutions.
METHODS
Composition of the WG (including patient and public 
involvement)
WG members were identified through several avenues. A 
rapid review was conducted by the project team in the 
project initiation phase to identify relevant patient organ-
isations, measurement initiatives, professional bodies 
and publications actively addressing questions relating 
to outcome measurement for COVID- 19 with a partic-
ular focus on patient- centred outcomes. Relevant organ-
isations were contacted and information about the role 
of WG members shared both directly as well as through 
social media channels. Open recruitment calls were then 
held inviting interested individuals to participate in the 
WG. A matrix of candidates was composed to facilitate 
the representation of diverse geographies, disciplines, 
types of expertise, and a balance of specialist interests, for 
example, infectious diseases, respiratory disease, mental 
health, primary care, intensive care. A shortlist was 
created that would represent different matrix cells, and 
ICHOM subsequently invited shortlisted individuals to 
participate. In addition, individuals or organisations were 
given the opportunity to recommend additional candi-
dates for consideration by the ICHOM project team.
Development of the COVID-19 standard set
The WG convened during six teleconferences between 
July 2020 and September 2020, following a structured 
process similar to that of previous ICHOM WGs. The 
development of the standard set involved four phases, 
as illustrated in figure 1: defining the scope of the 
project; prioritising outcome domains; defining outcome 
domains; and evaluating and selecting outcome measures 
that would be used to measure these domains, including 
clinical data and patient- reported outcome measures 
(PROMs); and selecting and defining case- mix variables.
Identification of potential outcomes, outcome measures and 
case-mix variables
The MEDLINE database was used to search for relevant 
publications from which potential outcome domains, 
outcome measures, PROMs and case- mix variables were 
extracted in order to generate a long- list for the WG to 
consider. The search strategy used for the MEDLINE 
search was:
((‘COVID- 19’[Title]) OR (‘novel coronavirus’[Title])) 
AND (‘Outcome’[Title]).
Two members of the project team (WHS and NS) 
carried out the MEDLINE search using the above strategy 
on 1 July 2020, and included papers published in English 
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Outcomes measured in published trials (apart from 
reviews which were excluded in order to generate a list 
of primary outcomes from trials) were extracted as well 
as outcomes being measured in ongoing trials, as iden-
tified by the WHO International Clinical Trials Registry 
Platform (ICTRP) database.8 Studies involving specific 
populations, such as gender, ethnicity, as well as interven-
tions targeting specific clinical outcomes, for example, 
resolution of fever, and laboratory- based outcome 
measures such as inflammatory markers were excluded 
as these were deemed by the WG to represent process 
measures rather than outcomes that in and of themselves 
mattered directly to patients. In addition to extracting the 
outcomes, the outcome measures used to measure these 
outcomes in the trials included were also extracted. These 
outcome measures were discussed after the outcomes 
themselves had been selected.
In addition, an electronic survey was distributed at the 
start of the project to patients and patient representatives, 
through WG members’ healthcare institutions, in line with 
their ethical guidelines (see online supplemental file 1). It 
was also distributed through the ICHOM newsletter and 
social media platforms, as well as to the European Heart 
Network and European Lung Foundation patient fora, in 
order to identify any additional outcomes that were of partic-
ular importance to patients. Finally, outcomes were extracted 
from previously published ICHOM standard sets that were of 
potential relevance to patients with COVID- 19, for example, 
patient- reported measures such as health- related quality of 
life, and clinical outcomes such as survival.
Consensus process
WG teleconferences were held every 2 weeks. Following 
each teleconference, the project team circulated an elec-
tronic survey via the Qualtrics platform to the WG to gather 
feedback on each key decision. An online modified Delphi 
process was performed over three rounds for the selection of 
outcomes, following the RAND/University of California (Los 
Angeles) methodology9 and based on a literature review,10 to 
achieve consensus on which outcomes should be included. 
Inclusion in the standard set required that at least 80% of the 
WG voted an item as ‘essential’ (score 7–9 on a 9- point Likert 
scale) in each voting round. WG members were given 1 week 
to complete each survey. Outcomes were excluded if at least 
80% of the WG voted an item as ‘not recommended’ (score 
1–3). Inconclusive domains were discussed and revised and 
put to a second round of voting. Outcomes that still had not 
garnered the required consensus for inclusion were put to a 
final third round vote. These three rounds were completed 
prior to considering the selection of outcome measures to 
capture the outcomes, which did not use the same Delphi 
methodology.
Selection of PROMs and case-mix variables
After PROs were chosen for inclusion in the standard set, 
corresponding measures were identified from the liter-
ature, from tools previously used in other ICHOM stan-
dard sets for similar outcome domains, and by outcome 
experts in the WG. The original and validation studies of 
the instruments were examined in order to evaluate the 
psychometric quality, domain coverage, and feasibility of 
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measurement and implementation. A breakout group 
consisting of academics and clinicians with particular 
expertise in PRO measures convened to decide on the 
most appropriate measures to use.
A different consensus- gathering process, this time 
requiring 70% consensus from the WG for each item, was 
used to agree on which measures and case- mix variables 
should be recommended in line with the methodology 
used in all ICHOM standard sets for this part of the study, 
as well as the time points for measuring each outcome. 
The 70% consensus level is thought to be sufficient for 
the selection of outcome measures and case- mix variables, 
whereas a more stringent threshold of 80% or more of 
the WG voting an outcome as ‘essential to include’ on 
the Likert scale is required in ICHOM methodology for 
the selection of the outcomes themselves. The results of 
each vote were reviewed by the WG at the subsequent 
teleconference. The criteria by which outcome domains 
were assessed for inclusion in the set were in accordance 
with the concepts of value- based healthcare as described 
by Porter.11 Variables to be used as case- mix factors were 




ICHOM established a geographically diverse WG covering 
a broad range of specialties relevant to COVID- 19. The 
WG consisted of 28 members, including clinicians, epide-
miologists, research scientists, and patients and patient 
advocates/representatives from 13 countries across 
North and South America, Europe, Africa, the Middle 
East, South Asia and Australia (table 1). A project team 
(WS, LF, NS, CN and KB) guided the efforts of the WG.
Scope
The outcomes and measures included in the COVID- 19 
standard set were defined for a target population of all 
adults over the age of 18 years with confirmed or highly 
suspected SARS- CoV- 2 infection, as defined by WHO,12 
in primary, secondary or tertiary care settings. Children 
under the age of 18 years, as well as asymptomatic indi-
viduals with positive diagnostic tests, were excluded from 
the set. Different geographical and resource contexts 
were considered so that the standard set can be applied 
globally.
Outcomes
About 86%, 89% and 82% of WG members participated 
in the first, second and third rounds of the modified 
Delphi process, respectively. Out of 64 possible outcomes 
(see online supplemental file 2) for a list of the sources 
of preliminary outcomes) identified through the method-
ology as described, the WG selected 13 outcomes. There 
was significant overlap between the outcomes identified 
from the different sources, and during the WG tele-
conferences, decisions were taken to merge or rename 
outcomes. The Reference Guide containing the defini-
tions of all outcome domains included, as agreed by the 
WG, is published on the ICHOM website at wwwichomorg. 
The outcomes were categorised into five major groups: 
functional status and quality of life, clinical outcomes, 
mental functioning, social functioning and symptoms. 
The set of outcomes and measures that were selected are 
detailed in table 1.
Each domain has a number of subdomains to capture 
what is important to patients. The domain on clinical 
outcomes is to be assessed by clinicians. For each of the 
remaining domains, the WG identified an appropriate 
outcome measure to use. Considering the overlap among 
measures, the WG identified the following measures: 
Patient- Reported Outcomes Measurement Information 
System (PROMIS) Global 1.2,13 PROMIS Social Isolation 
4a14 and FLU- PRO.15
Baseline characteristics and case-mix variables
In addition to the outcomes and outcome measures, 
the WG selected important baseline health characteris-
tics to enable comparison between providers (table 2). 
These baseline health characteristics include demo-
graphic factors, for example, age, sex, race, ethnicity, 
level of education, clinical factors, for example, comor-
bidities and body mass index, and treatment- related 
factors, for example, need for ventilation, type of venti-
lation, duration of ventilation, duration of critical care 
admission.
Timeline for follow-up
The WG decided to track patient outcomes over a 3- month 
period following the diagnosis or following criteria being 
met for highly suspected SARS- CoV- 2 infection (figure 2). 
The outcome collection period can be extended for a 
further 3 months if the patient has not yet fully recovered. 
The WG delegated to the treating physicians the decision 
whether or not to extend data collection.
DISCUSSION
In this project, an international WG developed a 
consensus set of the most important outcomes and 
outcome measures in COVID- 19. By measuring and 
reporting the same outcomes, and adjusting for the 
case- mix variables, providers may be able to improve the 
quality of care offered to patients by learning from other 
institutions using the same standard set. The standard 
set could also benefit patients directly by allowing them 
to track their progress over time and seek care when 
appropriate through heightened awareness of symptoms 
that they may not necessarily realise are problems, for 
example, mental health symptoms, or waning produc-
tivity. The standard set could also be considered for use 
in future respiratory viral pandemics.
This is the first global effort to develop a standardised 
minimum set of patient- centred outcomes in COVID- 19 
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about the long- term outcomes of the disease, this work 
provides a starting point and there is scope for additional 
measures to be included as our understanding of the 
disease improves. Other groups, including the WHO Clin-
ical Characterisation and Management Working Group, 
have sought to define sets of standardised outcomes in 
COVID- 19. This group published a core outcome set 
primarily for research use. As such, the outcomes recom-
mended by that group have a clinical and technical 
focus and include many indirect measures of patient 
outcomes.16 Our project focused on clinical practice, 
however, could also be used to inform real- world clinical 
research by incorporating direct patient outcomes, both 
in evaluating the course of illness and the effects of ther-
apeutics. This standard set is patient- centric, using PROs 
as a key component of the set, and focusing primarily on 
outcomes that matter to patients, for example, an individ-
ual’s ability to perform and/or participate in usual daily 
activities rather than on clinical metrics.
The predominant use of indirect outcomes in clinical 
trials of COVID- 19 and in monitoring patients’ progress with 
the disease runs the risk of missing issues of equal or more 
Table 1 Summary of ICHOM C19 standard set of outcomes
Outcome domain Outcome subdomains Definition Outcome measure
Functional status and 
quality of life
Health- related quality of life The perceived quality of an individual’s daily life, assessing 
their health and well- being or lack thereof. A multidimensional 
concept that includes domains related to physical, mental, 
emotional and social functioning.
PROMIS Global Health 
1.2
General physical functioning An individual’s ability to perform and/or participate in usual 
daily activities required to meet essential needs, fulfil usual 
roles, meet usual responsibilities, and maintain health and 
well- being.
PROMIS Global Health 
1.2
Vitality/energy Capacity for work and leisure activities, and efficiency of 
accomplishment related to a feeling of weariness or tiredness.
FLU- PRO
Mental functioning Mental health symptoms 
and emotional well- being
An individual’s emotional, psychological and social well- being, 
including negative feelings and fears, as well as moderate to 
high levels of anxiety or psychological distress.
PROMIS Global Health 
1.2
Cognitive status An individual’s mental process of knowing, including 
awareness, perception, reasoning and judgement.
Clinician measures
Social functioning Feelings of loneliness and 
isolation
An individual’s negative feelings related to the perception of 
being alone, disconnected or isolated.
PROMIS Social Isolation 
4 a
Productivity An individual’s ability to carry out tasks, actions or participate 
in life situations.
PROMIS Global Health 
1.2
Clinical outcomes Survival Any cause of death in a patient with COVID- 19. Clinician measures
Meeting criteria for critical 
care admission
Patients whose medical needs cannot be met through 
standard ward- based care in an acute hospital, who would 
meet criteria for a high dependency or critical care unit. 
Patients who meet criteria for critical care admission may not 
in fact be admitted to critical care facilities for other reasons, 
eg, resource constraints, however, should be included under 
this definition.
Clinician measures
Disease course severity Mild: No need for hospitalisation
Moderate: Hospitalisation without need for non- invasive or 
mechanical ventilation
Severe: Received non- invasive and/or mechanical ventilation, 
or died; admission to High Dependency Unit (HDU) or 
Intensive Care Unit (ICU).
Clinician measures
FLU- PRO
Persisting organ damage End- organ damage, including the central or peripheral 
nervous system, as a result of the COVID- 19 infection that 
results in impaired function in the individual.
Clinician measures
Duration of hospitalisation Number of nights spent in hospital being treated for 
symptoms related to COVID- 19 (irrespective of whether 
COVID- 19 was the reason for admission or if the patient 
developed COVID- 19 while in hospital for another reason). 
This includes nights spent in hospital on subsequent hospital 
admissions during the follow- up period if the individual 
being readmitted was being treated for symptoms related to 
COVID- 19 on that admission.
Clinician measures
Symptoms Symptoms A subjective perception suggesting bodily impairment or 
malfunction, affecting the individual in a negative manner.
FLU- PRO
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significance to those suffering with the illness— the disease 
burden of symptoms and impaired function that may persist 
long after the acute illness. While measuring survival and 
clinician- reported outcomes like hospitalisations is essential, 
it is equally important to measure PROs which add valuable 
information in those who do survive or who are discharged/
remain in hospital. PROs can be used for long- term follow- up 
to assess the effect of the disease on a patient’s quality of life, 
and to alert treating physicians to the development of compli-
cations.17 There is an increasing body of literature suggesting 
benefit to patients of various drugs and vaccines against 
COVID- 19. Validated, standardised PROs that comprehen-
sively assess the symptom experience and patient function in 
COVID- 19 across multiple domains could also facilitate meta- 
analyses and more precise estimates of treatment effects.
When considering which PRO measures to use in the set 
to measure overall quality of life, the WG felt that a generic 
as well as respiratory- specific measure would be most appro-
priate given the multisystem nature of COVID- 19. One 
such universal measurement system is the PROMIS. The 
PROMIS Global Health (V.1.2) instrument, which is freely 
available, consists of ten global health items that represent 
five core PROMIS domains (physical function, pain, fatigue, 
emotional distress, social health).18 The majority of PRO 
measures included in this set that are not symptoms are 
covered within the PROMIS Global Health questionnaire. 
One outcome that the WG felt important to include which is 
not adequately covered in this instrument is loneliness/isola-
tion, which is captured via the short PROMIS Social Isolation 
4a tool.
Table 2 Summary of COVID- 19 standard set case- mix variables
Case- mix category Variable Measure Timing Data source
Demographic factors Age Year of birth. Baseline Patient record
Sex The patient’s sex at birth.
Race The biological race of the patient. Patient record
Ethnicity The cultural ethnicity of the patient 
that they most closely identify with.
Level of education Highest level of education completed 
based on local standard definitions 
of education levels.
Patient record
Clinical factors Comorbidities Prior and current diagnosis of 
disease or no presence of diagnosis.
Baseline Patient/clinician






Need for ventilation Did the patient require any ventilation 





Type of ventilation What type of ventilation was 
administered?
Duration of ventilation How long did the patient require 
ventilation?
Duration of critical care 
admission
How long was the patient’s initial 
stay in critical care?
BMI, body mass index.
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In addition to the PROs included in the set, there are a 
number of clinical outcomes that the WG felt it essential to 
include. The WG felt it important to ensure that the direct 
endpoints used took account of the varying practices and 
resources that exist across the world. As such, the standard 
set is suitable for any primary, secondary or tertiary care 
setting in any country. Of note, while many COVID- 19 studies 
report Intensive Care Unit (ICU) admission as an outcome, 
the WG took the view that because ICU provision and there-
fore the thresholds for admission to ICU vary so signifi-
cantly depending on the context in which one practices, a 
more appropriate outcome measure would be ‘meeting 
criteria for ICU admission’ rather than admission itself that 
is, explaining the reason for ICU admission and not solely 
the event. A similar approach was taken when considering 
the issue of non- invasive ventilation, the use of which varied 
from being widespread to prohibited based on factors such 
as availability of oxygen and concerns around staff infection. 
The WG considered that ‘need for non- invasive ventilation,’ 
while important, could not be classed as an outcome since 
the criteria determining ‘need’ varied too much. Instead, this 
is included as a case- mix factor so that it can be controlled for 
in analyses.
The presence or absence of symptoms was included in the 
set on the basis that persistence of symptoms, for example, as 
part of ‘long COVID- 19’, may be modifiable and may repre-
sent a significant disease burden. The WG elected to use a 
symptom scale that has been developed and validated for 
comprehensively measuring symptoms in viral respiratory 
tract diseases—the FLU- PRO scale.15 The scale was devel-
oped with patient input and its psychometric properties have 
been evaluated in a study with over 500 patients including 
those with influenza virus, respiratory syncytial virus, entero-
virus, rhinovirus, adenovirus and endemic coronaviruses and 
is being used currently in studies of COVID- 19.19–21 The scale 
was adapted during COVID- 19, but in general, can be used to 
measure symptoms in any viral respiratory illness.
Consideration was given during WG discussions as to the 
appropriate timeline of data collection for patient symptoms. 
Although the FLU- PRO asks patients about symptoms in the 
previous 24 hours, the WG felt it infeasible to ask patients to 
rate their symptoms daily for the entire course of the 3- month 
follow- up period. The WG’s recommendation for practical 
use was to ask patients to complete the FLU- PRO fortnightly 
for the first month and then monthly thereafter, in line with 
the timeline for collection of other PRO measures as part of 
the ‘PROM package’ depicted in the timeline in figure 2.
An important aspect of this project is the standardisation of 
outcome measurement in COVID- 19 across differing regions 
and healthcare systems. To achieve this, we have published 
a comprehensive reference guide summarising the set, 
outcome reporting tools, adjustment variables and collection 
time points which is freely available at wwwichomorg.
Our approach does have some limitations. The stan-
dard set methodology is reliant on the composition of the 
WG. Although the WG recruited as diverse members as 
was possible given the time constraints, it is possible that a 
different WG would have come to different conclusions. Our 
methodology is reliant on the continued involvement of 
WG members over several months, and although we did not 
experience significant attrition during the various stages of 
the consensus- gathering process, nevertheless there remains 
the potential for attrition bias to have affected the results of 
the rounds of voting. Further, ICHOM standard sets typi-
cally undergo an open review process prior to publication in 
which the draft set is distributed to patients and their repre-
sentative groups for feedback. Unfortunately, this was not 
possible within the timeframe of this project. The standard 
set was developed not as a static document but firmly with 
implementation in mind. As such, feasibility of measuring 
outcomes was a key concern during the outcome selection 
stage and therefore not all outcomes could be included in 
the set, despite being recognised by some members of the 
WG as important. Furthermore, feasibility of measuring and 
global adoption of the set were important determinants of 
the symptom scales and PROs that were selected by the WG.
The next stage of this project is to promote implemen-
tation of the standard set. Issues to overcome when consid-
ering implementing the COVID- 19 set include: (1) budget; 
(2) availability of clinical leaders to champion the set and 
promote its adoption given pressing clinical commitments to 
direct patient care in the ongoing pandemic; (3) ensuring 
efficient and intuitive means of collecting and storing clinical 
data; and (4) ensuring consistent and accurate collection of 
PROs. Implementation of the set involves several phases as 
described previously.22
CONCLUSION
We have developed a consensus recommendation for a stan-
dardised minimum set of outcomes that our WG considered 
most important to patients with COVID- 19 comprising func-
tional status and quality of life, clinical outcomes, mental 
functioning, social functioning and symptoms. The use of 
PROs is central to the set and makes the recommendations 
particularly relevant. This standard set is targeted for integra-
tion into routine clinical practice and research. Use of the 
set may enable institutions to monitor, compare, and most 
importantly improve the quality of the care they deliver for 
patients with COVID- 19 as the pandemic unfolds.
Patient and public involvement
Patients and members of the public were involved at the 
centre of the work described in this manuscript. Patients 
were at the heart of the WG that produced the standard set, 
and patients (and their representatives at patient organisa-
tions) were directly asked which outcomes they felt were most 
important for them at the start of the project. Most of these 
outcomes are included in the final list of outcomes selected 
by the WG. The patient members of the WG contributed to 
the review and final drafts of this manuscript.
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